Market Chatter: Gates Foundation, PAHO Eye Expanded Access to Weight-Loss Drugs in Lower-Income Countries

MT Newswires Live

Oct 10

The Gates Foundation and the Pan American Health Organization, or PAHO, are looking to expand access to weight-loss drugs, like Eli Lilly's (LLY) tirzepatide and Novo Nordisk's (NVO) semaglutide, in lower income countries, Reuters reported Friday.

Reuters cited separate interviews with Microsoft (MSFT) founder Bill Gates and PAHO director Jarbas Barbosa.

The Gates Foundation could help provide data for the drugs' expansion by supporting clinical trials that will assess the medicines' effect on different populations, Reuters cited Gates as saying.

Meanwhile, Barbosa told Reuters that PAHO is "starting the conversation" over expanded access to the weight-loss drugs and plans to speak with Eli Lilly, Novo Nordisk, and generic drugmakers within the next few weeks.

Eli Lilly and Novo Nordisk did not immediately respond to MT Newswires' requests for comments.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2574717805"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2574717805\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2574717805?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-10 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2574717805","market":"hk","top_or_hot":-1,"title":"Market Chatter: Gates Foundation, PAHO Eye Expanded Access to Weight-Loss Drugs in Lower-Income Countries","media":"MT Newswires Live","content":"<html><body><p> The Gates Foundation and the Pan American Health Organization, or PAHO, are looking to expand access to weight-loss drugs, like Eli Lilly's (LLY) tirzepatide and <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s (NVO) semaglutide, in lower income countries, Reuters reported Friday.</p><p>Reuters cited separate interviews with Microsoft (MSFT) founder Bill Gates and PAHO director Jarbas Barbosa.</p><p>The Gates Foundation could help provide data for the drugs' expansion by supporting clinical trials that will assess the medicines' effect on different populations, Reuters cited Gates as saying.</p><p>Meanwhile, Barbosa told Reuters that PAHO is \"starting the conversation\" over expanded access to the weight-loss drugs and plans to speak with Eli Lilly, Novo Nordisk, and generic drugmakers within the next few weeks.</p><p>Eli Lilly and Novo Nordisk did not immediately respond to MT Newswires' requests for comments.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Market Chatter: Gates Foundation, PAHO Eye Expanded Access to Weight-Loss Drugs in Lower-Income Countries</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarket Chatter: Gates Foundation, PAHO Eye Expanded Access to Weight-Loss Drugs in Lower-Income Countries\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-10 19:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> The Gates Foundation and the Pan American Health Organization, or PAHO, are looking to expand access to weight-loss drugs, like Eli Lilly's (LLY) tirzepatide and <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s (NVO) semaglutide, in lower income countries, Reuters reported Friday.</p><p>Reuters cited separate interviews with Microsoft (MSFT) founder Bill Gates and PAHO director Jarbas Barbosa.</p><p>The Gates Foundation could help provide data for the drugs' expansion by supporting clinical trials that will assess the medicines' effect on different populations, Reuters cited Gates as saying.</p><p>Meanwhile, Barbosa told Reuters that PAHO is \"starting the conversation\" over expanded access to the weight-loss drugs and plans to speak with Eli Lilly, Novo Nordisk, and generic drugmakers within the next few weeks.</p><p>Eli Lilly and Novo Nordisk did not immediately respond to MT Newswires' requests for comments.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SGXZ99366536.SGD","symbol_name":"United Global Innovation A Acc SGD-H","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2574717805","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2574717805","pubTimestamp":1760095846,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"The Gates Foundation and the Pan American Health Organization, or PAHO, are looking to expand access to weight-loss drugs, like Eli Lilly's  tirzepatide and Novo Nordisk's  semaglutide, in lower income countries, Reuters reported Friday.Reuters cited separate interviews with Microsoft  founder Bill Gates and PAHO director Jarbas Barbosa.The Gates Foundation could help provide data for the drugs' expansion by supporting clinical trials that will assess the medicines' effect on different populations, Reuters cited Gates as saying.Meanwhile, Barbosa told Reuters that PAHO is \"starting the conversation\" over expanded access to the weight-loss drugs and plans to speak with Eli Lilly, Novo Nordisk, and generic drugmakers within the next few weeks.Eli Lilly and Novo Nordisk did not immediately respond to MT Newswires' requests for comments.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU0061474705.USD":"THREADNEEDLE (LUX) GLOBAL DYNAMIC REAL RETURN \"AU\" (USD) ACC","IE00BQXX3D17.EUR":"GUINNESS GLOBAL INNOVATORS \"C\" (EUR) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","BK4592":"伊斯兰概念","BK4577":"网络游戏","IE00BQXX3C00.GBP":"GUINNESS GLOBAL INNOVATORS \"C\" (GBP) ACC","LU0308772762.SGD":"Blackrock Global Allocation A2 SGD-H","IE000ITXATA3.USD":"PIMCO BALANCED INCOME AND GROWTH \"M\" (USD) ACC","IE00BKDWB100.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5H\" (SGDHDG) ACC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","BK4550":"红杉资本持仓","IE000YTNTUN2.SGD":"PIMCO BALANCED INCOME AND GROWTH \"M\" (SGDHDG)INC","LU1697837992.HKD":"BGF DYNAMIC HIGH INCOME \"A6\" (HKDHDG) INC","LLY":"礼来","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU1633808545.USD":"ALLIANZ GLOBAL EQUITY GROWTH \"AT\" (USD) ACC","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","LU0385154629.USD":"贝莱德营养科学基金A2","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU2191332357.HKD":"SCHRODER ISF SUSTAINABLE MULTI-ASSET INCOME \"A\" (HKDHDG) INC","LU1983260115.SGD":"Janus Henderson Horizon Global Sustainable Equity A2 SGD-H","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0175139822.USD":"AB FCP I Global Equity Blend A USD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2756315318.SGD":"ALLIANZ INCOME AND GROWTH \"AMG\" (SGDHDG) INC A","LU1196500208.SGD":"NORDEA STABLE RETURN \"HB\" (SGDHDG) ACC","BK4532":"文艺复兴科技持仓","LU0894486033.HKD":"SCHRODER ISF GLOBAL MULTI-ASSET INCOME \"A\" (HKD) INC MF","LU0061474960.USD":"天利环球焦点基金AU Acc","LU2487616109.SGD":"JPM AMERICA EQUITY \"A\" (SGD) ACC","NVO.AU":"NOVO RESOURCES CORP-CDI","NVO":"诺和诺德","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC"},"translate_title":"市场热议：盖茨基金会、泛美卫生组织着眼于扩大低收入国家获得减肥药的机会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1,"NVO":1,"NVO.AU":1},"content_text":"The Gates Foundation and the Pan American Health Organization, or PAHO, are looking to expand access to weight-loss drugs, like Eli Lilly's (LLY) tirzepatide and Novo Nordisk's (NVO) semaglutide, in lower income countries, Reuters reported Friday.Reuters cited separate interviews with Microsoft (MSFT) founder Bill Gates and PAHO director Jarbas Barbosa.The Gates Foundation could help provide data for the drugs' expansion by supporting clinical trials that will assess the medicines' effect on different populations, Reuters cited Gates as saying.Meanwhile, Barbosa told Reuters that PAHO is \"starting the conversation\" over expanded access to the weight-loss drugs and plans to speak with Eli Lilly, Novo Nordisk, and generic drugmakers within the next few weeks.Eli Lilly and Novo Nordisk did not immediately respond to MT Newswires' requests for comments.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}